Product Revenues, Net (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Valuation and Qualifying Accounts Disclosure [Line Items]
Customer deposits	$ 190,272	$ 73,416
Product Revenue Allowance and Reserve [Roll Forward]
Balance at December 31, 2016	89,201
Provision related to current period sales	153,209
Adjustments related to prior period sales	(4,883)
Credits/payments made	(127,632)
Balance at September 30, 2017	109,895
Trade Allowances
Product Revenue Allowance and Reserve [Roll Forward]
Balance at December 31, 2016	2,568
Provision related to current period sales	18,776
Adjustments related to prior period sales	(188)
Credits/payments made	(18,409)
Balance at September 30, 2017	2,747
Rebates, Chargebacks and Discounts
Product Revenue Allowance and Reserve [Roll Forward]
Balance at December 31, 2016	81,927
Provision related to current period sales	118,592
Adjustments related to prior period sales	(4,327)
Credits/payments made	(97,393)
Balance at September 30, 2017	98,799
Product Returns
Product Revenue Allowance and Reserve [Roll Forward]
Balance at December 31, 2016	3,492
Provision related to current period sales	3,603
Adjustments related to prior period sales	(13)
Credits/payments made	(1,809)
Balance at September 30, 2017	5,273
Other Incentives
Product Revenue Allowance and Reserve [Roll Forward]
Balance at December 31, 2016	1,214
Provision related to current period sales	12,238
Adjustments related to prior period sales	(355)
Credits/payments made	(10,021)
Balance at September 30, 2017	3,076
Cystic Fibrosis Foundation Therapeutics Incorporated
Valuation and Qualifying Accounts Disclosure [Line Items]
Customer deposits	$ 190,300